As of May 30, 2025
Amplify ETF Trust Amplify Weight Loss Drug & Treatment ETF (ARCA: THNR)
Ticker | Name | Share % | |
---|---|---|---|
LLY | Eli Lilly & Co. | 13.95% | |
CO | Novo Nordisk A/S ADR | 13.90% | |
LN | Developed Markets Astrazeneca Plc Sponsored Adr | 4.66% | |
AMGN | Amgen Inc. | 4.60% | |
PFE | Pfizer, Inc. | 4.69% | |
JP | Chugai Pharmaceutical Co Ltd | 5.60% | |
SM | Roche Holding Ag | 4.64% | |
MRK | Merck & Co. Inc. | 4.77% | |
WST | West Pharmaceutical Services Inc | 4.67% | |
TMO | Thermo Fisher Scientific Inc | 5.01% | |
SH | Innovent Biologics Inc | 6.61% | |
TEVA | Teva Pharmaceutical Industries Ltd | 5.18% | |
HIMS | Hims & Hers Health Inc | 6.67% |
The THNR ETF is currently trading at $22.59, which represents a -0.30% change. Over the past 52 weeks, the ETF has traded as high as $28.19 and as low as $18.56.
The expense ratio of THNR is 0.59%. This represents the annual fee that all funds or ETFs charge their shareholders.
The total Assets Under Management (AUM) for THNR is 2.93M. This represents the total market value of the assets managed by the ETF.
THNR follows a Large Cap Blend investment style.
The top holdings of THNR include: LLY (13.95%), CO (13.9%), LN (4.66%), AMGN (4.6%), PFE (4.69%). These represent the largest positions in the ETF's portfolio.
Average daily volume data for THNR is currently not available.